GRHL2: A Protein Involved in Growth, Development and Cancer (G79977)

Target Name: GRHL2

NCBI ID: G79977

GRHL2

GRHL2: A Protein Involved in Growth, Development and Cancer

Growth and development are critical processes in the life of all living beings, and the hormones play a vital role in regulating these processes. Growth and development are the natural outcomes of life, and the hormones help to ensure that the body grows and develops in a healthy and orderly manner. Hormones are chemical messengers that are produced by the endocrine system and are sent to other parts of the body to carry out specific functions. One of the hormones that plays a crucial role in growth and development is Growth and Developmental Hormone Receptor (GRHL2).

GRHL2 is a protein that is expressed in many different tissues throughout the body, including the brain, spinal cord, heart, and bones. It is a member of the TGF-β family of proteins, which are known for their role in cell growth, differentiation, and survival. In addition to its role in growth and development, GRHL2 has also been shown to play a number of important roles in maintaining tissue homeostasis and regulating inflammation.

As a drug target

GRHL2 is a drug target that has been identified for its potential to treat a number of different conditions. One of the primary targets for GRHL2 is its role in the development and progression of cancer. Cancer is a leading cause of death and disability in the world, and there is a need for new and effective treatments to address this devastating disease.

GRHL2 has been shown to play a role in the development of various types of cancer, including neurobladder cancer, breast cancer, and colon cancer. It has also been shown to promote the growth and survival of cancer cells.

In addition to its role in cancer development, GRHL2 has also been shown to contribute to the development of other diseases and conditions. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It has also been shown to play a role in the development of diseases of the heart, such as heart failure and hypertension.

As a biomarker

GRHL2 has also been shown to be a useful biomarker for a number of different conditions. For example, it has been shown to be involved in the development of various types of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development of diseases of the heart, such as heart failure and hypertension.

In addition to its use as a drug target and biomarker, GRHL2 has also been shown to have a number of potential therapeutic applications. For example, it has been shown to be involved in the regulation of cell growth and differentiation, which could make it a useful target for treatments aimed at repairing or regenerating damaged tissue. It has also been shown to play a role in the regulation of inflammation, which could make it a useful target for treatments aimed at reducing inflammation and preventing the development of chronic diseases.

Conclusion

GRHL2 is a protein that has been shown to play a number of important roles in the development and progression of a wide range of diseases. Its role as a drug target and biomarker makes it an attractive target for researchers and clinicians working to develop new and effective treatments for a variety of conditions. As more research is conducted on GRHL2, it is likely to become an increasingly important area of research and treatment.

Protein Name: Grainyhead Like Transcription Factor 2

Functions: Transcription factor playing an important role in primary neurulation and in epithelial development (PubMed:29309642, PubMed:25152456). Binds directly to the consensus DNA sequence 5'-AACCGGTT-3' acting as an activator and repressor on distinct target genes (By similarity). During embryogenesis, plays unique and cooperative roles with GRHL3 in establishing distinct zones of primary neurulation. Essential for closure 3 (rostral end of the forebrain), functions cooperatively with GRHL3 in closure 2 (forebrain/midbrain boundary) and posterior neuropore closure (By similarity). Regulates epithelial morphogenesis acting as a target gene-associated transcriptional activator of apical junctional complex components. Up-regulates of CLDN3 and CLDN4, as well as of RAB25, which increases the CLDN4 protein and its localization at tight junctions (By similarity). Comprises an essential component of the transcriptional machinery that establishes appropriate expression levels of CLDN4 and CDH1 in different types of epithelia. Exhibits functional redundancy with GRHL3 in epidermal morphogenetic events and epidermal wound repair (By similarity). In lung, forms a regulatory loop with NKX2-1 that coordinates lung epithelial cell morphogenesis and differentiation (By similarity). In keratinocytes, plays a role in telomerase activation during cellular proliferation, regulates TERT expression by binding to TERT promoter region and inhibiting DNA methylation at the 5'-CpG island, possibly by interfering with DNMT1 enzyme activity (PubMed:19015635, PubMed:20938050). In addition, impairs keratinocyte differentiation and epidermal function by inhibiting the expression of genes clustered at the epidermal differentiation complex (EDC) as well as GRHL1 and GRHL3 through epigenetic mechanisms (PubMed:23254293)

The "GRHL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRHL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets